(NASDAQ: VERA) Vera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.23%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.33%.
Vera Therapeutics's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast VERA's revenue for 2026 to be $1,584,405,181, with the lowest VERA revenue forecast at $163,899,586, and the highest VERA revenue forecast at $3,386,407,790. On average, 5 Wall Street analysts forecast VERA's revenue for 2027 to be $11,656,513,051, with the lowest VERA revenue forecast at $4,752,450,254, and the highest VERA revenue forecast at $27,605,282,032.
In 2028, VERA is forecast to generate $26,544,207,591 in revenue, with the lowest revenue forecast at $15,258,605,043 and the highest revenue forecast at $46,500,289,564.